Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT

View Full Paper
Ask AI
Bookmark
Share

Authors

LXLanping XuXZXiaohui ZhangXZXiang‐Yu Zhao

Discussion

Loading...

Member takes

Overview

Multicenter comparison shows BLI, CAR-T, and INO yield similar outcomes in R/R B-ALL prior to HSCT, suggesting uniform safety and efficacy.

Key Points

  • CAR-T recipients had a significantly higher rate of CMV reactivation at 56.3% compared to 39.3% in others, indicating a need for vigilant monitoring.
  • Statistical analyses and multivariable Cox proportional hazards models were utilized to assess survival and complications in B-ALL patients undergoing allo-HSCT.
  • Blinded, randomized approaches revealed no significant differences in overall survival or disease-free survival among blinatumomab, CAR-T, and inotuzumab ozogamicin treatments.
  • This analysis confirms comparable effectiveness of various immunotherapies as bridging treatments in R/R B-ALL, although CMV reactivation risk varies.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5fahttps://doi.org/10.1182/blood-2025-4298
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia2025 · 1 citations
  2. 2Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025
  3. 3Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy2025
  4. 4CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  5. 5Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors2025